Document:

Exhibit 4.5

  

  

  

  
    DESCRIPTION OF SECURITIES

    

    

    The following description of the securities of Altimeter Growth Corp. (the “Company,” “we” or “us”) is
      a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company’s amended and restated memorandum and article of association and our warrant agreement with American Stock Transfer & Trust
      Company, as warrant agent (the” warrant agreement”), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.5 is a part. We encourage you to read the memorandum and articles of association
      and the warrant agreement for additional information.

    

    

    DESCRIPTION OF SECURITIES

     

    We are a Cayman Islands exempted company and our affairs are governed by our amended and restated memorandum and articles of association,
      the Companies Law and the common law of the Cayman Islands. Pursuant to our amended and restated memorandum and articles of association, we are authorized to issue 200,000,000 Class A ordinary shares and 20,000,000 Class B ordinary shares, as well as
      1,000,000 preference shares, $0.0001 par value each. The following description summarizes the material terms of our shares as set out more particularly in our amended and restated memorandum and articles of association. Because it is only a summary,
      it may not contain all the information that is important to you.

     

    Units

     

    Each unit consists of one Class A ordinary share and one-fifth of one redeemable warrant. Each whole warrant entitles the holder thereof
      to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of the company’s Class A ordinary shares. This means
      only a whole warrant may be exercised at any given time by a warrant holder.

     

    Ordinary Shares

     

    62,500,000 of our ordinary shares are outstanding including:

    	

          	•	
            50,000,000 Class A ordinary shares underlying the units issued as part of our initial offering; and

          

    	

          	•	
            12,500,000 Class B ordinary shares held by our sponsor and independent directors.

          

     

    Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as
      described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except as required by law. Unless specified in our amended and
      restated memorandum and articles of association, or as required by applicable provisions of the Companies Law or applicable stock exchange rules, the affirmative vote of a majority of our ordinary shares that are voted is required to approve any such
      matter voted on by our shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of our ordinary
      shares that are voted, and pursuant to our amended and restated memorandum and articles of association; such actions include amending our amended and restated memorandum and articles of association and approving a statutory merger or consolidation
      with another company. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. Our
      shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Before our initial business combination, only holders of our founder shares will have the right to vote
      to appoint directors. Holders of our public shares will not be entitled to vote to appoint directors during such time. In addition, before the completion of an initial business combination, holders of a majority of our founder shares may remove a
      member of the board of directors for any reason. In addition, in a vote to continue the company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of our
      Class B ordinary shares will have ten votes for every Class B ordinary share and holders of our Class A ordinary shares will have one vote for every Class A ordinary share. The provisions of our amended and restated memorandum and articles of
      association governing the appointment or removal of directors before our initial business combination and our continuation in a jurisdiction outside the Cayman Islands before our initial business combination may only be amended by a special
      resolution passed by not less than two-thirds of the ordinary shares who attend and vote at our general meeting which shall include the affirmative vote of a simple majority of our Class B ordinary shares.

     

    
      
        

    

    Because our amended and restated memorandum and articles of association authorize the issuance of up to 200,000,000 Class A ordinary
      shares, if we were to enter into a business combination, we may (depending on the terms of such a business combination) be required to increase the number of Class A ordinary shares which we will be authorized to issue at the same time as our
      shareholders vote on the business combination to the extent we seek shareholder approval in connection with our initial business combination.

     

    In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual general meeting until one year after
      our first fiscal year end following our listing on Nasdaq. There is no requirement under the Companies Law for us to hold annual or general meetings to appoint directors. We may not hold an annual general meeting to appoint new directors before the
      closing of our initial business combination. Before the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, before the
      completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason.

     

    Our public shareholders may redeem all or a portion of their Class A
        ordinary shares upon our initial business combination’s completion at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days before the closing of our initial
        business combination, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitations
        described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting
        commissions we will pay to the underwriters. The redemption rights will include the requirement that a beneficial owner must identify itself in order to valid redeem its shares. Our sponsor and each member of our management team have entered into
        an agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to any founder shares and public shares held by them in connection with (i) the completion of our initial business combination, and (ii) a
        shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their
        shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months (or 27 months, as applicable) from the closing of our initial
      public offering or during any Extension Period or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares. Unlike many
        blank check companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial business combinations and provide for related redemptions of public shares for cash upon completion of such initial business
        combinations even when a vote is not required by law, if a shareholder vote is not required by applicable law or stock exchange listing requirements and we do not decide to hold a shareholder vote for business or other reasons, we will, pursuant to
        our amended and restated memorandum and articles of association, conduct the redemptions pursuant to the
        tender offer rules of the SEC, and file tender offer documents with the SEC before completing our initial business combination. Our amended and restated memorandum and articles of association require these tender offer documents to contain
        substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, a shareholder approval of the transaction is required by applicable law
        or stock exchange listing requirements, or we decide to obtain shareholder approval for business or other reasons, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules
        and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if we obtain the approval of an ordinary resolution under Cayman Islands law, being the affirmative vote of a
        majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at a general meeting. However, the participation of our sponsor, officers, directors, advisors or their affiliates in privately-negotiated
        transactions, if any, could result in the approval of our initial business combination even if a majority of our public shareholders vote, or indicate their intention to vote, against such initial business combination. For purposes of seeking
        approval of the majority of our issued and outstanding ordinary shares, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. Our amended and restated memorandum and articles of association
        require that at least five days’ notice will be given of any general meeting.

     

    
      
        

    

    If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial
      business combination pursuant to the tender offer rules, our amended and restated memorandum and articles of association provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder
      is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to Excess Shares, without our prior consent. However, we would not be restricting our shareholders’
      ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Our shareholders’ inability to redeem the Excess Shares will reduce their influence over our ability to complete our initial business
      combination, and such shareholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such shareholders will not receive redemption distributions with respect to the Excess Shares if we
      complete our initial business combination. And, as a result, such shareholders will continue to hold that number of shares exceeding 15% and, in order to dispose such shares would be required to sell their shares in open market transactions,
      potentially at a loss.

     

    If we seek shareholder approval, we will complete our initial business combination only if we obtain the approval of an ordinary
      resolution under Cayman Islands law, being the affirmative vote of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at a general meeting. In such case, our sponsor and each member of our
      management team have agreed to vote their founder shares and public shares in favor of our initial business combination. Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against
      the proposed transaction or vote at all.

     

    Pursuant to our amended and restated memorandum and articles of association, if we have not consummated an initial business combination
      within 24 months (or 27 months, as applicable) from the closing of our initial public offering, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days
      thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay
      our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the
      right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in
      the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. Our sponsor and each member of our management team have entered into an agreement with us, pursuant to which they have agreed to waive their rights to liquidating distributions from the trust account with respect to any founder shares they hold if we fail to
      consummate an initial business combination within 24 months (or 27 months, as applicable) from the closing of our initial public offering or during any Extension Period (although they will be entitled to liquidating distributions from the trust
      account with respect to any public shares they hold if we fail to complete our initial business combination within the prescribed time frame). Our amended and restated memorandum and articles of association provide that, if we wind up for any other
      reason before the closing of our initial business combination, we will follow the foregoing procedures with respect to the liquidation of the trust account as promptly as reasonably possible but not more than ten business days thereafter, subject to
      applicable Cayman Islands law.

     

    In the event of a liquidation, dissolution or winding up of the company after a business combination, our shareholders are entitled to
      share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of shares, if any, having preference over the ordinary shares. Our shareholders have no preemptive or
      other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the
      aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares,
      upon the completion of our initial business combination, subject to the limitations described herein.

     

    
      
        

    

    Founder Shares

     

    The founder shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A ordinary shares
      included in the units sold in our initial public offering, and holders of founder shares have the same shareholder rights as public shareholders, except that: (a) before our initial business combination, only holders of the founder shares have the
      right to vote to appoint directors and holders of a majority of our founder shares may remove a member of the board of directors for any reason; (b) the founder shares are subject to certain transfer restrictions, as described in more detail below;
      (c) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of our founder shares will have ten votes for every founder share and
      holders of our Class A ordinary shares will have one vote for every Class A ordinary share; (d) our sponsor and each member of our management team have entered into an agreement with us, pursuant to which they have agreed to (i) waive their
      redemption rights with respect to their founder shares (ii) to waive their redemption rights with respect to their founder shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum
      and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem
      100% of our public shares if we do not complete our initial business combination within 24 months (or 27 months, as applicable) from the closing of our initial public offering or (B) with respect to any other provision relating to the rights of
      holders of our Class A ordinary shares; and (iii) waive their rights to liquidating distributions from the trust account with respect to any founder shares they hold if we fail to consummate an initial business combination within 24 months (or 27
      months, as applicable) from the closing of our initial public offering or during any Extension Period (although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to
      complete our initial business combination within the prescribed time frame); (e) the founder shares will automatically convert into our Class A ordinary shares upon our initial business combination or earlier at the option of the holders thereof as
      described herein; and (f) the founder shares are entitled to registration rights. If we seek shareholder approval, we will complete our initial business combination only if we obtain the approval of an ordinary resolution under Cayman Islands law,
      being the affirmative vote of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at a general meeting. In such case, our sponsor and each member of our management team have agreed to vote
      their founder shares and public shares in favor of our initial business combination.

     

    The founder shares are designated as Class B ordinary shares and will automatically convert into Class A ordinary shares (which such
      Class A ordinary shares delivered upon conversion will not have redemption rights or be entitled to liquidating distributions from the trust account if we do not consummate an initial business combination) upon our initial business combination or
      earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an
      as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of our initial public offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon
      conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the closing of the initial business combination, excluding any forward purchase securities and Class A
      ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial business combination and any private placement warrants issued to our
      sponsor, its affiliates or any member of our management team upon conversion of working capital loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

     

    Except as described herein, our sponsor and our directors and executive officers have agreed not to transfer, assign or sell any of their
      founder shares until earliest of (A) one year after the completion of our initial business combination and (B) after our initial business combination, (x) if the closing price of our Class A ordinary shares equals or exceeds $12.00 per share (as
      adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 120 days after our initial business combination, or (y) the date on
      which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees
      would be subject to the same restrictions and other agreements of our sponsor and our directors and executive officers with respect to any founder shares.

     

    Before our initial business combination, only holders of our founder shares will have the right to vote to appoint directors. Holders of
      our public shares will not be entitled to vote to appoint directors during such time. In addition, before the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for
      any reason. These provisions of our amended and restated memorandum and articles of association may only be amended by a special resolution passed by not less than two-thirds of our ordinary shares who attend and vote at our general meeting which
      shall include the affirmative vote of a simple majority of our Class B ordinary shares. With respect to any other matter submitted to a vote of our shareholders, including any vote in connection with our initial business combination, except as
      required by law, holders of our founder shares and holders of our public shares will vote together as a single class, with each share entitling the holder to one vote.

     

    
      
        

    

    Register of Members

     

    Under Cayman Islands law, we must keep a register of members and there will be entered therein:

     

    	

          	•	
            the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of
              each member and the voting rights of shares of each member;

          

    	

          	•	
            the date on which the name of any person was entered on the register as a member; and

          

    	

          	•	
            the date on which any person ceased to be a member.

          

     

    Under Cayman Islands law, the register of members of our company is prima
        facie evidence of the matters set out therein (i.e., the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter of Cayman
        Islands law to have legal title to the shares as set against its name in the register of members. Upon the closing of our initial public offering, the register of members was updated to reflect the issue of shares by us and  the shareholders
        recorded in the register of members are deemed to have legal title to the shares set against their name. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the
        register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not
        reflect the correct legal position. If an application for an order for rectification of the register of members was made in respect of our ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.

     

    Preference Shares

     

    Our amended and restated memorandum and articles of association authorize 1,000,000 preference shares and provide that preference shares
      may be issued from time to time in one or more series. Our board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any
      qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the
      voting power and other rights of the holders of the ordinary shares and could have anti-takeover effects. The ability of our board of directors to issue preference shares without shareholder approval could have the effect of delaying, deferring or
      preventing a change of control of us or the removal of existing management. We have no preference shares issued and outstanding at the date hereof. Although we do not currently intend to issue any preference shares, we cannot assure you that we will
      not do so in the future.

     

    Warrants

     

    Public Shareholders’ Warrants

     

    Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to
      adjustment as discussed below, at any time commencing on the later of one year from the closing of our initial public offering and 30 days after the completion of our initial business combination, except as discussed in the immediately succeeding
      paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants
      will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least five units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the completion
      of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

     

    
      
        

    

    We will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to
      settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our
      obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and we will not be obligated to issue a Class A ordinary share upon exercise of a warrant unless the Class A
      ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two
      immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash
      settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class A ordinary share
      underlying such unit.

     

    We have agreed that as soon as practicable, but in no event later than twenty business days after the closing of our initial business
      combination, we will use our commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and we will use our
      commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of our initial business combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to
      those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange
      such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with
      Section 3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but we will use our commercially reasonably efforts to register or qualify the shares under
      applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective
      registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but we will use our commercially reasonably efforts
      to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the
      lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the
      fair market value and (B) 0.361 per warrant. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day before the date on which the
      notice of exercise is received by the warrant agent.

     

    Redemption of warrants when the price per Class A
        ordinary share equals or exceeds $18.00. Once the warrants become exercisable, we may redeem the outstanding warrants (except as described in herein with respect to the private placement warrants):

     

    	

          	•	
            in whole and not in part;

          

    	

          	•	
            at a price of $0.01 per warrant;

          

    	

          	•	
            upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and

          

    	

          	•	
            if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable
              upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Shareholders’ Warrants-Anti-Dilution Adjustments”) for any 10 trading days within a 20-trading day period ending on the third trading day before
              the date on which we send the notice of redemption to the warrant holders.

          

     

    We will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the
      Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. If and when the warrants become redeemable by
      us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.

     

    
      
        

    

    We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the
      call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant before the scheduled
      redemption date. Any such exercise would not be done on a “cashless” basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. However, the price of the Class A ordinary shares may fall below
      the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Shareholders’ Warrants-Anti-dilution Adjustments”) as
      well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.

     

    Redemption of warrants when the price per Class A
        ordinary share equals or exceeds $10.00. Once the warrants become exercisable, we may redeem the outstanding warrants (except as described herein with respect to the private placement warrants):

     

    	

          	•	
            in whole and not in part;

          

    	

          	•	
            at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided
              that holders will be able to exercise their warrants on a cashless basis before redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of our
              Class A ordinary shares (as defined below) except as otherwise described below; and

          

    	

          	•	
            if, and only if, the closing price of our Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares
              issuable upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Shareholders’ Warrants-Anti-Dilution Adjustments”) for any 10 trading days within the 20-trading day period ending three trading days
              before we send the notice of redemption to the warrant holders.

          

     

    Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their
      warrants on a cashless basis. The numbers in the table below represent the number of Class A ordinary shares that a warrant holder will receive upon such cashless exercise in connection with a
      redemption by us pursuant to this redemption feature, based on the “fair market value” of our Class A ordinary shares on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10
      per warrant), determined for these purposes based on volume weighted average price of our Class A ordinary shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of
      warrants, and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair market value no later than one
      business day after the 10-trading day period described above ends.

     

    Pursuant to the warrant agreement, references above to Class A ordinary shares shall include a security other than Class A ordinary
      shares into which the Class A ordinary shares have been converted or exchanged for in the event we are not the surviving company in our initial business combination. The numbers in the table below will not be adjusted when determining the number of
      Class A ordinary shares to be issued upon exercise of the warrants if we are not the surviving entity following our initial business combination.

     

    The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares
      issuable upon exercise of a warrant or the exercise price of a warrant is adjusted as set forth under the heading “-Anti-dilution Adjustments” below. If the number of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices
      in the column headings will equal the share prices immediately before such adjustment, multiplied by a fraction, the numerator of which is the exercise price of the warrant after such adjustment and the denominator of which is the price of the
      warrant immediately before such adjustment. In such an event, the number of shares in the table below shall be adjusted by multiplying such share amounts by a fraction, the numerator of which is the number of shares deliverable upon exercise of a
      warrant immediately before such adjustment and the denominator of which is the number of shares deliverable upon exercise of a warrant as so adjusted. If the exercise price of a warrant is adjusted, (a) in the case of an adjustment pursuant to the
      fifth paragraph under the heading “-Anti-dilution Adjustments” below, the adjusted share prices in the column headings will equal the unadjusted share price multiplied by a fraction, the numerator of which is the higher of the Market Value and the
      Newly Issued Price as set forth under the heading “ -Anti-dilution Adjustments” and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to the second paragraph under the heading “-Anti-dilution Adjustments” below, the
      adjusted share prices in the column headings will equal the unadjusted share price less the decrease in the exercise price of a warrant pursuant to such exercise price adjustment.

     

    

    
      
        

    

    	
            Redemption Date

          	
            ​

          	
            ​

          	
            Fair Market Value of Class A Ordinary Shares

          
	
            (period to expiration of warrants)

          	
            ​

          	
            ​

          	
            <10.00

          	
            ​

          	
            ​

          	
            11.00

          	
            ​

          	
            ​

          	
            12.00

          	
            ​

          	
            ​

          	
            13.00

          	
            ​

          	
            ​

          	
            14.00

          	
            ​

          	
            ​

          	
            15.00

          	
            ​

          	
            ​

          	
            16.00

          	
            ​

          	
            ​

          	
            17.00

          	
            ​

          	
            ​

          	
            >18.00

          
	
            60 months

          	
            ​

          	
            ​

          	
            0.261

          	
            ​

          	
            ​

          	
            0.281

          	
            ​

          	
            ​

          	
            0.297

          	
            ​

          	
            ​

          	
            0.311

          	
            ​

          	
            ​

          	
            0.324

          	
            ​

          	
            ​

          	
            0.337

          	
            ​

          	
            ​

          	
            0.348

          	
            ​

          	
            ​

          	
            0.358

          	
            ​

          	
            ​

          	
            0.361

          
	
            57 months

          	
            ​

          	
            ​

          	
            0.257

          	
            ​

          	
            ​

          	
            0.277

          	
            ​

          	
            ​

          	
            0.294

          	
            ​

          	
            ​

          	
            0.310

          	
            ​

          	
            ​

          	
            0.324

          	
            ​

          	
            ​

          	
            0.337

          	
            ​

          	
            ​

          	
            0.348

          	
            ​

          	
            ​

          	
            0.358

          	
            ​

          	
            ​

          	
            0.361

          
	
            54 months

          	
            ​

          	
            ​

          	
            0.252

          	
            ​

          	
            ​

          	
            0.272

          	
            ​

          	
            ​

          	
            0.291

          	
            ​

          	
            ​

          	
            0.307

          	
            ​

          	
            ​

          	
            0.322

          	
            ​

          	
            ​

          	
            0.335

          	
            ​

          	
            ​

          	
            0.347

          	
            ​

          	
            ​

          	
            0.357

          	
            ​

          	
            ​

          	
            0.361

          
	
            51 months

          	
            ​

          	
            ​

          	
            0.246

          	
            ​

          	
            ​

          	
            0.268

          	
            ​

          	
            ​

          	
            0.287

          	
            ​

          	
            ​

          	
            0.304

          	
            ​

          	
            ​

          	
            0.320

          	
            ​

          	
            ​

          	
            0.333

          	
            ​

          	
            ​

          	
            0.346

          	
            ​

          	
            ​

          	
            0.357

          	
            ​

          	
            ​

          	
            0.361

          
	
            48 months

          	
            ​

          	
            ​

          	
            0.241

          	
            ​

          	
            ​

          	
            0.263

          	
            ​

          	
            ​

          	
            0.283

          	
            ​

          	
            ​

          	
            0.301

          	
            ​

          	
            ​

          	
            0.317

          	
            ​

          	
            ​

          	
            0.332

          	
            ​

          	
            ​

          	
            0.344

          	
            ​

          	
            ​

          	
            0.356

          	
            ​

          	
            ​

          	
            0.361

          
	
            45 months

          	
            ​

          	
            ​

          	
            0.235

          	
            ​

          	
            ​

          	
            0.258

          	
            ​

          	
            ​

          	
            0.279

          	
            ​

          	
            ​

          	
            0.298

          	
            ​

          	
            ​

          	
            0.315

          	
            ​

          	
            ​

          	
            0.330

          	
            ​

          	
            ​

          	
            0.343

          	
            ​

          	
            ​

          	
            0.356

          	
            ​

          	
            ​

          	
            0.361

          
	
            42 months

          	
            ​

          	
            ​

          	
            0.228

          	
            ​

          	
            ​

          	
            0.252

          	
            ​

          	
            ​

          	
            0.274

          	
            ​

          	
            ​

          	
            0.294

          	
            ​

          	
            ​

          	
            0.312

          	
            ​

          	
            ​

          	
            0.328

          	
            ​

          	
            ​

          	
            0.342

          	
            ​

          	
            ​

          	
            0.355

          	
            ​

          	
            ​

          	
            0.361

          
	
            39 months

          	
            ​

          	
            ​

          	
            0.221

          	
            ​

          	
            ​

          	
            0.246

          	
            ​

          	
            ​

          	
            0.269

          	
            ​

          	
            ​

          	
            0.290

          	
            ​

          	
            ​

          	
            0.309

          	
            ​

          	
            ​

          	
            0.325

          	
            ​

          	
            ​

          	
            0.340

          	
            ​

          	
            ​

          	
            0.354

          	
            ​

          	
            ​

          	
            0.361

          
	
            36 months

          	
            ​

          	
            ​

          	
            0.213

          	
            ​

          	
            ​

          	
            0.239

          	
            ​

          	
            ​

          	
            0.263

          	
            ​

          	
            ​

          	
            0.285

          	
            ​

          	
            ​

          	
            0.305

          	
            ​

          	
            ​

          	
            0.323

          	
            ​

          	
            ​

          	
            0.339

          	
            ​

          	
            ​

          	
            0.353

          	
            ​

          	
            ​

          	
            0.361

          
	
            33 months

          	
            ​

          	
            ​

          	
            0.205

          	
            ​

          	
            ​

          	
            0.232

          	
            ​

          	
            ​

          	
            0.257

          	
            ​

          	
            ​

          	
            0.280

          	
            ​

          	
            ​

          	
            0.301

          	
            ​

          	
            ​

          	
            0.320

          	
            ​

          	
            ​

          	
            0.337

          	
            ​

          	
            ​

          	
            0.352

          	
            ​

          	
            ​

          	
            0.361

          
	
            30 months

          	
            ​

          	
            ​

          	
            0.196

          	
            ​

          	
            ​

          	
            0.224

          	
            ​

          	
            ​

          	
            0.250

          	
            ​

          	
            ​

          	
            0.274

          	
            ​

          	
            ​

          	
            0.297

          	
            ​

          	
            ​

          	
            0.316

          	
            ​

          	
            ​

          	
            0.335

          	
            ​

          	
            ​

          	
            0.351

          	
            ​

          	
            ​

          	
            0.361

          
	
            27 months

          	
            ​

          	
            ​

          	
            0.185

          	
            ​

          	
            ​

          	
            0.214

          	
            ​

          	
            ​

          	
            0.242

          	
            ​

          	
            ​

          	
            0.268

          	
            ​

          	
            ​

          	
            0.291

          	
            ​

          	
            ​

          	
            0.313

          	
            ​

          	
            ​

          	
            0.332

          	
            ​

          	
            ​

          	
            0.350

          	
            ​

          	
            ​

          	
            0.361

          
	
            24 months

          	
            ​

          	
            ​

          	
            0.173

          	
            ​

          	
            ​

          	
            0.204

          	
            ​

          	
            ​

          	
            0.233

          	
            ​

          	
            ​

          	
            0.260

          	
            ​

          	
            ​

          	
            0.285

          	
            ​

          	
            ​

          	
            0.308

          	
            ​

          	
            ​

          	
            0.329

          	
            ​

          	
            ​

          	
            0.348

          	
            ​

          	
            ​

          	
            0.361

          
	
            21 months

          	
            ​

          	
            ​

          	
            0.161

          	
            ​

          	
            ​

          	
            0.193

          	
            ​

          	
            ​

          	
            0.223

          	
            ​

          	
            ​

          	
            0.252

          	
            ​

          	
            ​

          	
            0.279

          	
            ​

          	
            ​

          	
            0.304

          	
            ​

          	
            ​

          	
            0.326

          	
            ​

          	
            ​

          	
            0.347

          	
            ​

          	
            ​

          	
            0.361

          
	
            18 months

          	
            ​

          	
            ​

          	
            0.146

          	
            ​

          	
            ​

          	
            0.179

          	
            ​

          	
            ​

          	
            0.211

          	
            ​

          	
            ​

          	
            0.242

          	
            ​

          	
            ​

          	
            0.271

          	
            ​

          	
            ​

          	
            0.298

          	
            ​

          	
            ​

          	
            0.322

          	
            ​

          	
            ​

          	
            0.345

          	
            ​

          	
            ​

          	
            0.361

          
	
            15 months

          	
            ​

          	
            ​

          	
            0.130

          	
            ​

          	
            ​

          	
            0.164

          	
            ​

          	
            ​

          	
            0.197

          	
            ​

          	
            ​

          	
            0.230

          	
            ​

          	
            ​

          	
            0.262

          	
            ​

          	
            ​

          	
            0.291

          	
            ​

          	
            ​

          	
            0.317

          	
            ​

          	
            ​

          	
            0.342

          	
            ​

          	
            ​

          	
            0.361

          
	
            12 months

          	
            ​

          	
            ​

          	
            0.111

          	
            ​

          	
            ​

          	
            0.146

          	
            ​

          	
            ​

          	
            0.181

          	
            ​

          	
            ​

          	
            0.216

          	
            ​

          	
            ​

          	
            0.250

          	
            ​

          	
            ​

          	
            0.282

          	
            ​

          	
            ​

          	
            0.312

          	
            ​

          	
            ​

          	
            0.339

          	
            ​

          	
            ​

          	
            0.361

          
	
            9 months

          	
            ​

          	
            ​

          	
            0.090

          	
            ​

          	
            ​

          	
            0.125

          	
            ​

          	
            ​

          	
            0.162

          	
            ​

          	
            ​

          	
            0.199

          	
            ​

          	
            ​

          	
            0.237

          	
            ​

          	
            ​

          	
            0.272

          	
            ​

          	
            ​

          	
            0.305

          	
            ​

          	
            ​

          	
            0.336

          	
            ​

          	
            ​

          	
            0.361

          
	
            6 months

          	
            ​

          	
            ​

          	
            0.065

          	
            ​

          	
            ​

          	
            0.099

          	
            ​

          	
            ​

          	
            0.137

          	
            ​

          	
            ​

          	
            0.178

          	
            ​

          	
            ​

          	
            0.219

          	
            ​

          	
            ​

          	
            0.259

          	
            ​

          	
            ​

          	
            0.296

          	
            ​

          	
            ​

          	
            0.331

          	
            ​

          	
            ​

          	
            0.361

          

     

    	
            Redemption Date

          	
            ​

          	
            ​

          	
            Fair Market Value of Class A Ordinary Shares

          
	
            (period to expiration of warrants)

          	
            ​

          	
            ​

          	
            <10.00

          	
            ​

          	
            ​

          	
            11.00

          	
            ​

          	
            ​

          	
            12.00

          	
            ​

          	
            ​

          	
            13.00

          	
            ​

          	
            ​

          	
            14.00

          	
            ​

          	
            ​

          	
            15.00

          	
            ​

          	
            ​

          	
            16.00

          	
            ​

          	
            ​

          	
            17.00

          	
            ​

          	
            ​

          	
            >18.00

          
	
            3 months

          	
            ​

          	
            ​

          	
            0.034

          	
            ​

          	
            ​

          	
            0.065

          	
            ​

          	
            ​

          	
            0.104

          	
            ​

          	
            ​

          	
            0.150

          	
            ​

          	
            ​

          	
            0.197

          	
            ​

          	
            ​

          	
            0.243

          	
            ​

          	
            ​

          	
            0.286

          	
            ​

          	
            ​

          	
            0.326

          	
            ​

          	
            ​

          	
            0.361

          
	
            0 months

          	
            ​

          	
            ​

          	
            -

          	
            ​

          	
            ​

          	
            -

          	
            ​

          	
            ​

          	
            0.042

          	
            ​

          	
            ​

          	
            0.115

          	
            ​

          	
            ​

          	
            0.179

          	
            ​

          	
            ​

          	
            0.233

          	
            ​

          	
            ​

          	
            0.281

          	
            ​

          	
            ​

          	
            0.323

          	
            ​

          	
            ​

          	
            0.361

          

     

    The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is
      between two values in the table or the redemption date is between two redemption dates in the table, the number of Class A ordinary shares to be issued for each warrant exercised will be determined by a straight-line interpolation between the number
      of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or 366-day year, as applicable. For example, if the volume weighted average price of our Class A ordinary shares
      for the 10 trading days ending on the third trading day before the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders
      may choose to, in connection with this redemption feature, exercise their warrants for 0.277 Class A ordinary shares for each whole warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above,
      if the volume weighted average price of our Class A ordinary shares for the 10 trading days ending on the third trading day before the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time
      there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.298 Class A ordinary shares for each whole warrant. In no event will the warrants be
      exercisable on a cashless basis in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money and about to
      expire, they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any Class A ordinary shares.

     

    
      
        

    

    This redemption feature differs from the typical warrant redemption features used in many other blank check offerings, which typically
      only provide for a redemption of warrants for cash (other than the private placement warrants) when the trading price for the Class A ordinary shares exceeds $18.00 per share for a specified period of time. This redemption feature is structured to
      allow for all of the outstanding warrants to be redeemed when the Class A ordinary shares are trading at or above $10.00 per public share, which may be at a time when the trading price of our Class A ordinary shares is below the exercise price of the
      warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold set forth above under “-Redemption of warrants when the price per
      Class A ordinary share equals or exceeds $18.00.” Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model
      with a fixed volatility input. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding
      and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we
      determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.

     

    As stated above, we can redeem the warrants when the Class A ordinary shares are trading at a price starting at $10.00, which is below
      the exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of
      shares. If we choose to redeem the warrants when the Class A ordinary shares are trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer Class A ordinary shares than they would have
      received if they had chosen to wait to exercise their warrants for Class A ordinary shares if and when such Class A ordinary shares were trading at a price higher than the exercise price of $11.50.

     

    No fractional Class A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional
      interest in a share, we will round down to the nearest whole number of the number of Class A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares
      pursuant to the warrant agreement (for instance, if we are not the surviving company in our initial business combination), the warrants may be exercised for such security. At such time as the
      warrants become exercisable for a security other than the Class A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the
      warrants.

     

    Redemption procedures.

     

    A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
      right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as
      a holder may specify) of the Class A ordinary shares issued and outstanding immediately after giving effect to such exercise.

     

    Anti-dilution Adjustments. If the number of
      outstanding Class A ordinary shares is increased by a capitalization or share dividend payable in Class A ordinary shares, or by a split-up of ordinary shares or other similar event, then, on the effective date of such capitalization or share
      dividend, split-up or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all
      holders of ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the “historical fair market value” (as defined below) will be deemed a share dividend of a number of Class A ordinary shares equal to the product of
      (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) and (ii) one minus the
      quotient of (x) the price per Class A ordinary share paid in such rights offering and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares,
      in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) “historical fair market value”
      means the volume weighted average price of Class A ordinary shares as reported during the 10 trading day period ending on the trading day before the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable
      market, regular way, without the right to receive such rights.

     

    
      
        

    

    In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash,
      securities or other assets to all or substantially all of the holders of the Class A ordinary shares on account of such Class A ordinary shares (or other securities into which the warrants are convertible), other than (a) as described above, (b) any
      cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class A ordinary shares during the 365-day period ending on the date of declaration of such dividend or
      distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class A ordinary shares
      issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c) to satisfy the redemption rights of the holders of Class A ordinary shares in
      connection with a proposed initial business combination, (d) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a shareholder vote to amend our amended and restated memorandum and articles of association (A)
      to modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not
      complete our initial business combination within 24 months (or 27 months, as applicable) from the closing of our initial public offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares, or
      (e) in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount
      of cash and/or the fair market value of any securities or other assets paid on each Class A ordinary share in respect of such event.

     

    If the number of outstanding Class A ordinary shares is decreased by a consolidation, combination, reverse share sub-division or
      reclassification of Class A ordinary shares or other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division, reclassification or similar event, the number of Class A ordinary shares issuable on
      exercise of each warrant will be decreased in proportion to such decrease in outstanding Class A ordinary shares.

     

    Whenever the number of Class A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant
      exercise price will be adjusted by multiplying the warrant exercise price immediately before such adjustment by a fraction (x) the numerator of which will be the number of Class A ordinary shares purchasable upon the exercise of the warrants
      immediately before such adjustment and (y) the denominator of which will be the number of Class A ordinary shares so purchasable immediately thereafter.

     

    In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities, excluding the forward purchase securities,
      for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good
      faith by our board of directors and, in the case of any such issuance to our sponsor or its affiliates, without taking into account any founder shares held by our sponsor or such affiliates, as applicable, before such issuance) (the “Newly Issued
      Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the closing of our initial business
      combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the 20 trading day period starting on the trading day before the day on which we consummate our initial business combination
      (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption
      trigger price described above under “-Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” and “-Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the
      nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described above under “-Redemption of warrants when the price per Class A ordinary share equals or
      exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

     

    
      
        

    

    In case of any reclassification or reorganization of the outstanding Class A ordinary shares (other than those described above or that
      solely affects the par value of such Class A ordinary shares), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not
      result in any reclassification or reorganization of our outstanding Class A ordinary shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an
      entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the Class A ordinary
      shares immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of Class A ordinary shares or other securities or property (including cash) receivable upon such reclassification,
      reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately before such event. However, if such
      holders were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets for which each warrant will
      become exercisable will be deemed to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively make such election, and if a tender, exchange or redemption offer has been made
      to and accepted by such holders (other than a tender, exchange or redemption offer made by the company in connection with redemption rights held by shareholders of the company as provided for in the company’s amended and restated memorandum and
      articles of association or as a result of the redemption of Class A ordinary shares by the company if a proposed initial business combination is presented to the shareholders of the company for approval) under circumstances in which, upon completion
      of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker (within
      the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the issued and
      outstanding Class A ordinary shares, the holder of a warrant will be entitled to receive the highest amount of cash, securities or other property to which such holder would actually have been entitled as a shareholder if such warrant holder had
      exercised the warrant before the expiration of such tender or exchange offer, accepted such offer and all of the Class A ordinary shares held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustment (from and after the closing of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in the warrant agreement. If less than 70% of
      the consideration receivable by the holders of Class A ordinary shares in such a transaction is payable in the form of Class A ordinary shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an
      established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such
      transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional
      value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants. The purpose of such
      exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full
      potential value of the warrants.

     

    The warrants were issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant
      agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or correct any mistake, including to conform the provisions of the warrant
      agreement to the description of the terms of the warrants and the warrant agreement set forth in the registration statement filed with the Securities and Exchange Commission on Form S-1,
        File No. 333-248762, as amended (the “prospectus”) in connection with out initial public offering, or defective provision (ii) amending the provisions relating to cash dividends on ordinary shares as contemplated by and in accordance with
      the warrant agreement or (iii) adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not
      adversely affect the rights of the registered holders of the warrants, provided that the approval by the holders of at least 50% of the then-outstanding public warrants is required to make any change that adversely affects the interests of the
      registered holders. You should review a copy of the warrant agreement, which has been filed as an exhibit to this Annual Report on Form 10-K, for a complete description of the terms and conditions applicable to the warrants.

     

    
      
        

    

    The warrant holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their
      warrants and receive Class A ordinary shares. After the issuance of Class A ordinary shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.

     

    No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants,
      a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the number of Class A ordinary shares to be issued to the warrant holder.

     

    We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the
      warrant agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive
      forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the
      sole and exclusive forum.

     

    Private Placement Warrants

     

    Except as described below, the private placement warrants have terms and provisions that are identical to those of the warrants being
      sold as part of the units in our initial public offering. The private placement warrants (including the Class A ordinary shares issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days
      after the completion of our initial business combination (except pursuant to limited exceptions to our officers and directors and other persons or entities affiliated with the initial purchasers
      of the private placement warrants) and they will not be redeemable by us so long as they are held by our sponsor or its permitted transferees. Our sponsor, or its permitted transferees, has the option to exercise the private placement warrants on a
      cashless basis. If the private placement warrants are held by holders other than our sponsor or its permitted transferees, the private placement warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same
      basis as the warrants included in the units sold in our initial public offering. Any amendment to the terms of the private placement warrants or any provision of the warrant agreement with respect to the private placement warrants will require a vote
      of holders of at least 50% of the number of the then outstanding private placement warrants.

     

    If holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by
      surrendering his, her or its warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “Sponsor
      fair market value” (defined below) over the exercise price of the warrants by (y) the Sponsor fair market value. For these purposes, the “Sponsor fair market value” shall mean the average reported closing price of the Class A ordinary shares for the
      10 trading days ending on the third trading day before the date on which the notice of warrant exercise is sent to the warrant agent. The reason that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held
      by our sponsor and its permitted transferees is because it is not known at this time whether they will be affiliated with us following a business combination. If they remain affiliated with us, their ability to sell our securities in the open market
      will be significantly limited. We expect to have policies in place that restrict insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an
      insider cannot trade in our securities if he or she is in possession of material non-public information. Accordingly, unlike public shareholders who could exercise their warrants and sell the Class A ordinary shares received upon such exercise freely
      in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is
      appropriate.

     

    In order to fund working capital deficiencies or finance transaction costs in connection with an intended initial business combination,
      our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. Up to $2,000,000 of such loans may be convertible into warrants of the post business combination
      entity at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the private placement warrants.

     

    
      
        

    

    Forward Purchase Securities

     

    We have entered into (a) a forward purchase agreement pursuant to which Altimeter Partners Fund, L.P. (the “forward purchase investor”)
      has agreed to subscribe for up to an aggregate of 17,500,000 forward purchase units, consisting of one Class A ordinary share, or one forward purchase share, and one-fifth of one warrant to purchase one Class A ordinary share, or one-fifth of one
      forward purchase warrant, for $10.00 per unit, or up to $175,000,000 in the aggregate, in a private placement to close substantially concurrently with our initial business combination’s closing and (b) a forward purchase agreement pursuant to which
      JS Capital will subscribe for up to an aggregate of 2,500,000 forward purchase units, consisting of one Class A ordinary share, or one forward purchase share, and one-fifth of one warrant to purchase one Class A ordinary share, or one-fifth of one
      forward purchase warrant, for $10.00 per unit, or up to $25,000,000 in the aggregate, in a private placement to close substantially concurrently with the closing of our initial business combination. The obligations under the forward purchase
      agreements do not depend on whether any Class A ordinary shares are redeemed by our public shareholders. Subject to the collective maximum-commitment limitation under the forward purchase agreements, we will determine in our sole discretion the
      specific number of forward purchase units that we sell to the forward purchase investors, if any. However, if we determine to sell fewer forward purchase units than that collective maximum-commitment limitation, then we will allocate the forward
      purchase units that we are selling to the forward purchase investors on a pro-rata basis according to their relative individual maximum forward purchase commitment amounts measured as a percentage of the collective maximum forward purchase commitment
      amount under both forward purchase agreements.

     

    The forward purchase agreements also provide that the forward purchase investors are entitled to registration rights with respect to (a)
      the forward purchase shares, (b) the Class A ordinary shares issuable upon exercise of the forward purchase warrants, and (c) any other Class A ordinary shares or warrants acquired by the forward purchase investors, including any acquired after we
      complete our initial business combination. Please see “Description of Securities-Registration and Shareholder Rights” for additional information. We may use the proceeds from our sale of the
      forward purchase units as part of the consideration to the sellers in our initial business combination, and/or for expenses in connection with our initial business combination, and/or for working capital in the post-business-combination company. The
      forward purchase investors are obligated to buy the forward purchase units, regardless of whether our public shareholders redeem any Class A ordinary shares, and our sale of any forward purchase units is intended to give us a minimum funding level
      for our initial business combination. The forward purchase securities will be issued only in connection with the initial business combination’s closing.

     

    Our forward purchase agreement with Altimeter Partners provides that Altimeter Partners may decline to purchase some or all of the
      forward purchase units if our sponsor and our sponsor's affiliates collectively own 25% or more of our outstanding shares when we initiate the private placement sale of forward purchase units.

     

    Dividends

     

    We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends before the completion of our
      initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition after completion of our initial business combination. The payment
      of any cash dividends after our initial business combination will be within the discretion of our board of directors at such time. Further, if we incur any indebtedness in connection with a business combination, our ability to declare dividends may
      be limited by restrictive covenants we may agree to in connection therewith.

     

    Our Transfer Agent and Warrant Agent

     

    The transfer agent for our ordinary shares and warrant agent for our warrants is Continental Stock Transfer & Trust Company. We have
      agreed to indemnify Continental Stock Transfer & Trust Company in its roles as transfer agent and warrant agent, its agents and each of its shareholders, directors, officers and employees against all claims and losses that may arise out of acts
      performed or omitted for its activities in that capacity, except for any claims and losses due to any gross negligence or intentional misconduct of the indemnified person or entity.

     

    
      
        

    

    Certain Differences in Corporate Law

     

    Cayman Islands companies are governed by the Companies Law. The Companies Law is modeled on English Law but does not follow recent
      English Law statutory enactments, and differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Companies Law applicable to us and the
      laws applicable to companies incorporated in the United States and their shareholders.

     

    Mergers and Similar Arrangements. In certain
      circumstances, the Companies Law allows for mergers or consolidations between two Cayman Islands companies, or between a Cayman Islands exempted company and a company incorporated in another jurisdiction (provided that is facilitated by the laws of that other jurisdiction).

     

    Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of
      merger or consolidation containing certain prescribed information. That plan or merger or consolidation must then be authorized by either (a) a special resolution (usually a majority of 66 2/3% in value of the voting shares voted at a general
      meeting) of the shareholders of each company; or (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. No shareholder resolution is required for a merger between a parent company (i.e., a
      company that owns at least 90% of the issued shares of each class in a subsidiary company) and its subsidiary company. The consent of each holder of a fixed or floating security interest of a constituent company must be obtained, unless the court
      waives such requirement. If the Cayman Islands Registrar of Companies is satisfied that the requirements of the Companies Law (which includes certain other formalities) have been complied with, the Registrar of Companies will register the plan of
      merger or consolidation.

     

    Where the merger or consolidation involves a foreign company, the procedure is similar, save that with respect to the foreign company,
      the directors of the Cayman Islands exempted company are required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the merger or consolidation is
      permitted or not prohibited by the constitutional documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws and any
      requirements of those constitutional documents have been or will be complied with; (ii) that no petition or other similar proceeding has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign
      company in any jurisdictions; (iii) that no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect of the foreign company, its affairs or its property or any part thereof; and (iv)
      that no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction whereby the rights of creditors of the foreign company are and continue to be suspended or restricted.

     

    Where the surviving company is the Cayman Islands exempted company, the directors of the Cayman Islands exempted company are further
      required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the foreign company is able to pay its debts as they fall due and that the merger or
      consolidated is bona fide and not intended to defraud unsecured creditors of the foreign company; (ii) that in respect of the transfer of any security interest granted by the foreign company to the surviving or consolidated company (a) consent or
      approval to the transfer has been obtained, released or waived; (b) the transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company; and (c) the laws of the jurisdiction of the foreign company
      with respect to the transfer have been or will be complied with; (iii) that the foreign company will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant foreign
      jurisdiction; and (iv) that there is no other reason why it would be against the public interest to permit the merger or consolidation.

     

    Where the above procedures are adopted, the Companies Law provides for a right of dissenting shareholders to be paid a payment of the
      fair value of his shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows: (a) the shareholder must give his written objection to the merger or consolidation to the
      constituent company before the vote on the merger or consolidation, including a statement that the shareholder proposes to demand payment for his shares if the merger or consolidation is authorized by the vote; (b) within 20 days following the date
      on which the merger or consolidation is approved by the shareholders, the constituent company must give written notice to each shareholder who made a written objection; (c) a shareholder must within 20 days following receipt of such notice from the
      constituent company, give the constituent company a written notice of his intention to dissent including, among other details, a demand for payment of the fair value of his shares; (d) within seven days following the date of the expiration of the
      period set out in paragraph (b) above or seven days following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to
      each dissenting shareholder to purchase his shares at a price that the company determines is the fair value and if the company and the shareholder agree the price within 30 days following the date on which the offer was made, the company must pay the
      shareholder such amount; and (e) if the company and the shareholder fail to agree a price within such 30 day period, within 20 days following the date on which such 30 day period expires, the company (and any dissenting shareholder) must file a
      petition with the Cayman Islands Grand Court to determine the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been
      reached by the company. At the hearing of that petition, the court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any
      dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances,
      for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date or where the consideration for such shares to be
      contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company.

     

    
      
        

    

    Moreover, Cayman Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain
      circumstances, schemes of arrangement will generally be more suited for complex mergers or other transactions involving widely held companies, commonly referred to in the Cayman Islands as a “scheme of arrangement” which may be tantamount to a
      merger. In the event that a merger was sought pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically required to consummate a merger in the United States), the
      arrangement in question must be approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made and who must in addition represent
      three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at an annual general meeting, or an extraordinary general meeting summoned for that purpose. The
      convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view that the transaction should not
      be approved, the court can be expected to approve the arrangement if it satisfies itself that:

     

    	

          	•	
            we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with;

          

    	

          	•	
            the shareholders have been fairly represented at the meeting in question;

          

    	

          	•	
            the arrangement is such as a businessman would reasonably approve; and

          

    	

          	•	
            the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Law or that would amount to a “fraud on the minority.”

          

     

    If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable
      to appraisal rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of United States corporations.

     

    Squeeze-out Provisions. When a takeover offer
      is made and accepted by holders of 90% of the shares to whom the offer relates within four months, the offeror may, within a two-month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection
      can be made to the Grand Court of the Cayman Islands, but this is unlikely to succeed unless there is evidence of fraud, bad faith, collusion or inequitable treatment of the shareholders.

     

    Further, transactions similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through means
      other than these statutory provisions, such as a share capital exchange, asset acquisition or control, or through contractual arrangements of an operating business.

     

    Shareholders’ Suits. Maples and Calder, our
      Cayman Islands legal counsel, is not aware of any reported class action having been brought in a Cayman Islands court.

     

    Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such
      actions. In most cases, we will be the proper plaintiff in any claim based on a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based both on Cayman Islands
      authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:

     

    
      
        

    

    	

          	•	
            a company is acting, or proposing to act, illegally or beyond the scope of its authority;

          

    	

          	•	
            the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been
              obtained; or

          

    	

          	•	
            those who control the company are perpetrating a “fraud on the minority.”

          

     

    A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are
      about to be infringed.

     

    Enforcement of Civil Liabilities. The Cayman
      Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States.

     

    We have been advised by Maples and Calder, our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i) to
      recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to
      impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although
      there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a
      foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain
      conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands
      judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or
      multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.

     

    Special Considerations for Exempted Companies. We
      are an exempted company with limited liability (meaning our public shareholders have no liability, as members of the company, for liabilities of the company over and above the amount paid for their shares) under the Companies Law. The Companies Law
      distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The
      requirements for an exempted company are essentially the same as for an ordinary company except for the exemptions and privileges listed below:

     

    	

          	•	
            annual reporting requirements are minimal and consist mainly of a statement that the company has conducted its operations mainly outside of the Cayman Islands and has
              complied with the provisions of the Companies Law;

          

    	

          	•	
            an exempted company’s register of members is not open to inspection;

          

    	

          	•	
            an exempted company does not have to hold an annual general meeting;

          

    	

          	•	
            an exempted company may issue negotiable or bearer shares or shares with no par value;

          

    	

          	•	
            an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);

          

    	

          	•	
            an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;

          

    	

          	•	
            an exempted company may register as a limited duration company; and

          

    	

          	•	
            an exempted company may register as a segregated portfolio company.

          

     

    
      
        

    

    Amended and Restated Memorandum and Articles of Association

     

    Our amended and restated memorandum and articles of association contain provisions designed to provide certain rights and protections
      that will apply to us until the completion of our initial business combination. These provisions cannot be amended without a special resolution under Cayman Islands law. As a matter of Cayman Islands law, a resolution is deemed to be a special
      resolution where it has been approved by either (i) the affirmative vote of at least two-thirds (or any higher threshold specified in a company’s articles of association) of a company’s shareholders entitled to vote and so voting at a general meeting
      for which notice specifying the intention to propose the resolution as a special resolution has been given; or (ii) if so authorized by a company’s articles of association, by a unanimous written resolution of all of the company’s shareholders. Other
      than as described above, our amended and restated memorandum and articles of association provide that special resolutions must be approved either by at least two-thirds of our shareholders who attend and vote at a general meeting of the company
      (i.e., the lowest threshold permissible under Cayman Islands law), or by a unanimous written resolution of all of our shareholders.

     

    Our initial shareholders and their permitted transferees, if any, who collectively beneficially own 20% of our ordinary shares upon the
      closing of our initial public offering (assuming they did not purchase any units in our initial public offering or since), will participate in any vote to amend our amended and restated memorandum and articles of association and will have the
      discretion to vote in any manner they choose. Specifically, our amended and restated memorandum and articles of association provide, among other things, that:

     

    	

          	•	
            If we have not consummated an initial business combination within 24 months (or 27 months, as applicable) from the closing of our initial public offering, we will (i)
              cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount
              then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes that were paid by us or are payable by us, if any (less up to $100,000 of
              interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation
              distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and
              (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law;

          

    	

          	•	
            Before or in connection with our initial business combination, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from
              the trust account or (ii) vote as a class with our public shares (a) on our initial business combination or on any other proposal presented to shareholders before or in connection with the completion of an initial business combination or (b)
              to approve an amendment to our amended and restated memorandum and articles of association to (x) extend the time we have to consummate a business combination beyond 24 months (or 27 months, as applicable) from the closing of our initial
              public offering or (y) amend the foregoing provisions;

          

    	

          	•	
            Although we do not intend to enter into a business combination with a target business that is affiliated with our sponsor, Founder, our directors or our officers, we
              are not prohibited from doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from independent investment banking firm or another independent entity that commonly renders
              valuation opinions that such a business combination is fair to our company from a financial point of view;

          

    	

          	•	
            If a shareholder vote on our initial business combination is not required by applicable law or stock exchange listing requirements and we do not decide to hold a
              shareholder vote for business or other reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC before completing our initial business
              combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act;

          

    	

          	•	
            So long as our securities are then listed on Nasdaq, our initial business combination must occur with one or more target businesses that together have an aggregate
              fair market value of at least 80% of the assets held in the trust account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the income earned on the trust account) at the time of the agreement to
              enter into the initial business combination;

          

     

    

    
      
        

    

    	

          	•	
            If our shareholders approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our
              obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business
              combination within 24 months (or 27 months, as applicable) from the closing of our initial public offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares, we will provide our public
              shareholders with the opportunity to redeem all or a portion of their ordinary shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on
              the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitations described herein; and

          

    	

          	•	
            We will not effectuate our initial business combination solely with another blank check company or a similar company with nominal operations.

          

     

    In addition, our amended and restated memorandum and articles of
        association provide that under no circumstances will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001.

     

    The Companies Law permits a company incorporated in the Cayman Islands to amend its memorandum and articles of association with the
      approval of a special resolution which requires the approval of the holders of at least two-thirds of such company’s issued and outstanding ordinary shares who attend and vote at a general meeting or by way of unanimous written resolution. A
      company’s articles of association may specify that the approval of a higher majority is required but, provided the approval of the required majority is obtained, any Cayman Islands exempted company may amend its memorandum and articles of association
      regardless of whether its memorandum and articles of association provide otherwise.

     

    Accordingly, although we could amend any of the provisions relating to our structure and business plan which are contained in our amended
      and restated memorandum and articles of association, we view all of these provisions as binding obligations to our shareholders and neither we, nor our officers or directors, will take any action to amend or waive any of these provisions unless we
      provide dissenting public shareholders with the opportunity to redeem their public shares.

     

    Privacy Notice

     

    Introduction

     

    This privacy notice puts our shareholders on notice that through your
        investment in the Company you will provide us with certain personal information which constitutes personal data within the meaning of the DPL (“personal data”). In the following discussion, the “company” refers to us and our affiliates and/or
        delegates, except where the context requires otherwise.

     

    Investor Data

     

    We will collect, use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that
      could be reasonably expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to conduct our activities of on an ongoing basis or to comply with legal and
      regulatory obligations to which we are subject. We will only transfer personal data in accordance with the requirements of the DPL, and will apply appropriate technical and organizational information security measures designed to protect against
      unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage to the personal data.

     

    In our use of this personal data, we will be characterized as a “data controller” for the purposes of the DPL, while our affiliates and
      service providers who may receive this personal data from us in the conduct of our activities may either act as our “data processors” for the purposes of the DPL or may process personal information for their own lawful purposes in connection with
      services provided to us.

     

    We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information
      relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax
      identification, credit history, correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder’s investment activity.

     

    
      
        

    

    Who this Affects

     

    If you are a natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal
      arrangements such as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation your investment in the company, this will be relevant for those individuals and you should
      transmit the content of this Privacy Notice to such individuals or otherwise advise them of its content.

     

    How the Company May Use a Shareholder’s Personal Data

     

    The company, as the data controller, may collect, store and use personal data for lawful purposes, including, in particular:

     

    	

          	(a)	
            where this is necessary for the performance of our rights and obligations under any purchase agreements;

          

    	

          	(b)	
            where this is necessary for compliance with a legal and regulatory obligation to which we are subject (such as compliance with anti-money laundering and FATCA/CRS
              requirements); and/or

          

    	

          	(c)	
            where this is necessary for the purposes of our legitimate interests and such interests are not overridden by your interests, fundamental rights or freedoms.

          

     

    Should we wish to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we
      will contact you.

     

    Why We May Transfer Your Personal Data

     

    In certain circumstances we may be legally obliged to share personal data and other information with respect to your shareholding with
      the relevant regulatory authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information with foreign authorities, including tax authorities.

     

    We anticipates disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain
      entities located outside the United States, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.

     

    The Data Protection Measures We Take

     

    Any transfer of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in
      accordance with the requirements of the DPL.

     

    We and our duly authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures
      designed to protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data.

     

    We shall notify you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or
      freedoms or those data subjects to whom the relevant personal data relates.

     

    Certain Anti-takeover Provisions of our amended and restated Memorandum and Articles of Association

     

    Our authorized but unissued Class A ordinary shares and preference shares will be available for future issuances without shareholder
      approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Class A ordinary shares and
      preference shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

     

    
      
        

    

    Securities Eligible for Future Sale

     

    We currently have 50,000,000 Class A ordinary shares issued and outstanding on an as-converted basis. These Class A ordinary shares sold
      in our initial public offering are freely tradable without restriction or further registration under the Securities Act, except for any Class A ordinary shares purchased by one of our affiliates within the meaning of Rule 144 under the Securities
      Act. All of the 12,500,000 outstanding founder shares  and all of the 12,000,000 outstanding private placement warrants  will be restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering.

     

    Upon the closing of the sale of the forward purchase units, all of the forward purchase shares, forward purchase warrants and Class A
      ordinary shares underlying the forward purchase warrants will be restricted securities under Rule 144.

     

    Rule 144

     

    Pursuant to Rule 144, a person who has beneficially owned restricted shares or warrants for at least six months would be entitled to sell
      their securities provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months
      preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the twelve months (or
      such shorter period as we were required to file reports) preceding the sale.

     

    Persons who have beneficially owned restricted shares or warrants for at least six months but who are our affiliates at the time of, or
      at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of:

     

    	

          	•	
            1% of the total number of ordinary shares then-outstanding, which equals 562,500 shares; or

          

    	

          	•	
            the average weekly reported trading volume of the Class A ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to
              the sale.

          

     

    Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of
      current public information about us.

     

    Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies

     

    Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell
      companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

     

    	

          	•	
            the issuer of the securities that was formerly a shell company has ceased to be a shell company;

          

    	

          	•	
            the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

          

    	

          	•	
            the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding twelve months (or such shorter
              period that the issuer was required to file such reports and materials), other than Form 8-K reports; and

          

    
      	 	
              •

            	
              at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an
                entity that is not a shell company.

            

    

     

    As a result, our sponsor will be able to sell its founder shares and private placement warrants, as applicable, pursuant to Rule 144
      without registration one year after we have completed our initial business combination.

     

    
      
        

    

    Registration and Shareholder Rights

     

    The holders of the founder shares, private placement warrants and any warrants that may be issued upon conversion of working capital
      loans (and any Class A ordinary shares issuable upon the exercise of the private placement warrants and warrants that may be issued upon conversion of working capital loans) are entitled to registration rights pursuant to a registration and
      shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with
      respect to registration statements filed after our completion of our initial business combination. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act
      to become effective until termination of the applicable lockup period, which occurs (i) in the case of the founder shares, as described in the following paragraph, and (ii) in the case of the private placement warrants and the respective Class A
      ordinary shares underlying such warrants, 30 days after the completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

     

    Pursuant to the forward purchase agreements, we will agree that we will use our commercially reasonable efforts to (i) within 30 days
      after the closing of the initial business combination, file a registration statement with the SEC for a secondary offering of (A) the forward purchase investor’s forward purchase shares, (B) the Class A ordinary shares issuable upon exercise of the
      forward purchase investor’s forward purchase warrants and (C) any other Class A ordinary shares acquired by the forward purchase investors, including any acquisitions after we complete our initial business combination, (ii) cause such registration
      statement to be declared effective promptly thereafter, but in no event later than 90 days after the closing of the initial business combination and (iii) maintain the effectiveness of such registration statement and to ensure the registration
      statement does not contain a material omission or misstatement, including by way of amendment or other update, as required, until the earlier of (A) the date on which a forward purchase investor ceases to hold the securities covered thereby and (B)
      the date all of the securities covered thereby can be sold publicly without restriction or limitation under Rule 144 under the Securities Act, and without the requirement to be in compliance with Rule 144(c)(1) under the Securities Act, subject to
      certain conditions and limitations set forth in the forward purchase agreements. We will bear the cost of registering these securities.

     

    Except as described herein, our sponsor and our directors and executive officers have agreed not to transfer, assign or sell their
      founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) after our initial business combination, (x) if the closing price of our Class A ordinary shares equals or exceeds $12.00 per share (as
      adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 120 days after our initial business combination, or (y) the date on
      which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash,
      securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of our sponsor with respect to any founder shares.

     

    In addition, pursuant to the registration and shareholder rights agreement, our sponsor, upon and following closing of an initial
      business combination, will be entitled to nominate three individuals for appointment to our board of directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement.

     

    Listing of Securities

     

    Our units, Class A ordinary shares, and warrants are listed on Nasdaq under the symbols “AGCUU,” “AGC,” and “AGCWW,” respectively. The
      units will automatically separate into their component parts and will not be traded following the completion of our initial business combination.Exhibit 10.1

 

NOTE PURCHASE AGREEMENT

This NOTE PURCHASE AGREEMENT (this “Agreement”)
is made and entered into as of March 24, 2021 by and among Summit Therapeutics Inc., a Delaware corporation, with its principal
place of business at One Broadway, 14th Floor, Cambridge, MA 02142 (the “Company”), and the investor
named on Exhibit A hereto (the “Investor”).

Recitals

A.
The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by the provisions of Regulation D, as promulgated by the U.S. Securities and Exchange Commission (the
 “SEC”) under the Securities Act of 1933, as amended;

B.
The Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor a Promissory
Note, in the form attached hereto as Exhibit B, in the original principal amount of $55,000,000 (the “Note”),
which shall mature and come due upon the earlier of (i) the consummation of a public offering of securities registered under the
Securities Act of 1933, as amended, by the Company with net proceeds of no less than $55,000,000 or (ii) thirteen (13) months from
the date hereof, upon the terms and conditions set forth in such Note; and

C.
This Agreement, the Note, and all other certificates, agreements, documents and instruments delivered to any party under
or in connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the
 “Transaction Documents”.

In consideration of the mutual promises
made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

1.
Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:

“Affiliate” means,
with respect to any Person, any other Person which directly or indirectly through one or more intermediaries controls, is controlled
by, or is under common control with, such Person. A Person shall be deemed to control another Person if such Person possesses,
directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through
the ownership of voting securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall
be deemed to control another Person if any of the following conditions is met: (i) in the case of corporate entities, direct or
indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors,
and (ii) in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity interest
with the power to direct the management and policies of such non-corporate entities.

“Agreement” has the
meaning set forth in the preamble to this Agreement.

“Board” means the
Company’s Board of Directors.

“Business Day” means
a day, other than a Saturday, Sunday or United States federal holiday, on which banks in New York City are open for the general
transaction of business.

    	 

     

    

“Closing” has the
meaning set forth in Section 3.1.

“Closing Date” has
the meaning set forth in Section 3.1.

“Common Stock” has
the meaning set forth in Section 4.2 to this Agreement.

“Common Stock Equivalents”
shall mean any options, warrants or other securities or rights convertible into or exercisable or exchangeable for, whether directly
or following conversion into or exercise or exchange for other options, warrants or other securities or rights, Common Stock of
the Company, or any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership
of, or voting or other rights of, Common Stock.

“Company” has the
meaning set forth in the preamble to this Agreement.

“Disposition” or “Dispose
of” shall mean any (i) pledge, sale, contract to sell, sale of any option or contract to purchase, purchase of any option
or contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any Common Stock
or any Common Stock Equivalents, including, without limitation, any “short sale” or similar arrangement, or (ii) swap
or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence
of ownership of the Common Stock or any Common Stock Equivalents, whether any such swap or transaction is to be settled by delivery
of securities, in cash or otherwise.

“Domestication” shall
mean the process by which the Company was formally confirmed as the successor issuer to Summit Therapeutics plc pursuant to a United
Kingdom court-approved scheme of arrangement effective as of September 18, 2020.

“Enforceability Exceptions”
has the meaning set forth in Section 4.4(b).

“GAAP” means generally accepted accounting principles in
the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of
Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles
as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances
as of the date of determination, consistently applied.

“Governmental Authority”
shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of
any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country
or any supranational organization of which any such country is a member.

“Group” means the
Company and its subsidiaries (and “Group Company” shall be construed accordingly).

“Investor” has the
meaning set forth in the preamble to this Agreement.

“Law” or “Laws”
shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions and/or ordinances of any Governmental Authority.

    	2

     

    

“Material Adverse Effect”
means a material adverse effect on (i) the assets, liabilities, results of operations, financial condition or business of
the Company and its subsidiaries taken as a whole, (ii) the legality or enforceability of this Agreement or (iii) the
ability of the Company to perform its obligations under this Agreement.

“Nasdaq” means The
Nasdaq Stock Market LLC.

“Person” means an
individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically
listed herein.

“Press Release” has
the meaning set forth in Section 10.7.

“Purchase Price” has
the meaning set forth in Section 2.1.

“Sarbanes-Oxley Act”
has the meaning set forth in Section 4.10(g).

“SEC” has the meaning
set forth in the recitals to this Agreement.

“SEC Documents” has
the meaning set forth in Section 4.10(a).

“Short Sales” means
all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be deemed to include the
location and/or reservation of borrowable Common Stock).

“Third Party” shall
mean any Person, including a Governmental Authority, other than the Investor, the Company or any Affiliate of the Investor or the
Company or any of their respective representatives.

“Trading Day” shall
mean a day on which trading in the Common Stock generally occurs on Nasdaq.

“Transaction Documents”
has the meaning set forth in the recitals to this Agreement.

“1933 Act” means the
Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

“1934 Act” means the
Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

“8-K Filing” has the
meaning set forth in Section 9.7.

2.
Purchase and Sale of the Note.

2.1.
Subject to the terms and conditions of this Agreement, the Investor hereby agrees to purchase, and the Company agrees to
issue and sell to the Investor the Note. In consideration therefor, the Investor shall pay the Company the aggregate amount of
fifty-five million U.S. dollars ($55,000,000) (the “Purchase Price”).

    	3

     

    

3.
Closing.

3.1.
The completion of the purchase and sale of the Note (the “Closing”) shall be on the date hereof (the
 “Closing Date”). The Closing shall occur remotely on the Closing Date via exchange of documents and signatures
or at such place as the Company and the Investor may agree in writing.

3.2.
On the Closing Date the Investor shall deliver or cause to be delivered to the Company the Purchase Price via wire transfer
of immediately available funds pursuant to the wire instructions delivered to the Investor by the Company in connection with the
execution of this Agreement. Upon the execution of this Agreement, the Company shall deliver or cause to be delivered the Note
duly executed by an authorized officer of the Company to the Investor.

4.
Representations and Warranties of the Company. The Company hereby represents and warrants to the Investor that, except
as otherwise described in this Agreement or the SEC Documents, which qualify these representations and warranties in their entirety:

4.1.
Organization, Good Standing and Qualification. The Company has been duly organized and is validly existing and in
good standing under the laws of its jurisdiction of organization, is duly qualified to do business and is in good standing in each
jurisdiction in which its ownership or lease of property or the conduct of its businesses requires such qualification, and has
all power and authority necessary to own or hold its properties and to conduct the businesses in which it is engaged, except where
the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate,
have a Material Adverse Effect.

4.2.
Capitalization and Voting Rights.

(a)
As of February 28, 2021, the Company has 82,887,802 shares of the Company’s Common Stock, par value $0.01 (the “Common
Stock”) issued and outstanding. The Company has also (i) granted outstanding options under the Company’s equity
incentive plans over, in aggregate, 11,688,768 shares of Common Stock, (ii) granted restricted stock units under the Company’s
directors’ remuneration policy over 0 shares of Common Stock and (iii) issued warrants for the purchase of up to 5,821,137
shares of Common Stock, which are outstanding as of February 28, 2021. The issued share capital of the Company has been duly and
validly issued and is fully paid and non-assessable.

(b)
Except as described or referred to in Section 4.2(a) above, as of the date of this Agreement, there are no outstanding rights
(including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable
for, any share capital or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement
of any kind relating to the issuance of any share capital of the Company, any such convertible or exchangeable securities or any
such rights, warrants or options.

(c)
No Person has any right to cause the Company to effect the registration under the 1933 Act of any securities of the Company,
which have not been exercised prior to the date hereof.

(d)
The Company is not a party to or subject to any agreement or understanding relating to the voting of share capital of the
Company or the giving of written consents by a stockholder or director of the Company.

    	4

     

    

(e)
The execution and delivery of this Agreement, and the transactions contemplated hereby, will not result in the triggering
of any anti-dilution rights, or otherwise increase the number of shares of Common Stock issuable or decrease the exercise or conversion
price, under any warrant, option, convertible note or other instruments convertible or exchangeable for, any share capital or other
equity interests in the Company.

4.3.
Subsidiaries. All the outstanding share capital or other equity interests of each subsidiary owned, directly or indirectly,
by the Company have been duly authorized and validly issued, are fully paid and are owned directly or indirectly by the Company,
free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any
third party.

4.4.
Authorization.

(a)
The Company has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken (including the approval of the Board and of the independent Special Committee of
the Board formed in connection with the Company’s consideration of the transactions undertaken pursuant to the Transaction
Documents) for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the
transactions contemplated hereby and thereby has been duly and validly taken.

(b)
This Agreement and the other Transaction Documents have been duly executed and delivered by the Company, and this Agreement
and the other Transaction Documents (as and when executed and delivered in accordance with the terms and conditions of the Agreement)
constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms,
except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights
generally or by equitable principles relating to enforceability (collectively, the “Enforceability Exceptions”).

(c)
No stop order or suspension of trading of the Company’s equity securities has been imposed by the SEC, Nasdaq, or
any other Governmental Authority and remains in effect.

4.5.
No Defaults. The Company is not (i) in violation of its certificate of incorporation or bylaws; (ii) in default,
and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or
observance of any term, covenant or condition contained in any indenture, mortgage or loan agreement to which the Company is a
party or by which the Company is bound or to which any of the property or assets of the Company is subject; (iii) in default, and
no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any deed of trust or other agreement or instrument to which the Company is a party
or by which the Company is bound or to which any of the property or assets of the Company is subject (except for any agreements
referred to in clause (ii) above); or (iv) in violation of any law or statute or any judgment, order, rule or regulation of any
court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries, except,
in the case of clauses (iii) and (iv) above, for any such default or violation that would not, individually or in the aggregate,
have a Material Adverse Effect.

    	5

     

    

4.6.
No Conflicts. The execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated hereby will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute
a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the
Company pursuant to, any indenture, mortgage or loan agreement to which the Company is a party or by which the Company is bound
or to which any of the property or assets of the Company is subject, (ii) conflict with or result in a breach or violation of any
of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to, any deed of trust or other agreement or instrument to which the Company
is a party or by which the Company is bound or to which any of the property or assets of the Company is subject (except for any
agreements referred to in clause (i) above), (iii) result in any violation of the provisions of the Company’s certificate
of incorporation or bylaws or (iv) result in the violation of any law or statute or any judgment, order, rule or regulation of
any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries,
except, in the case of clauses (ii) and (iv) above, for any such conflict, breach, violation or default that would not, individually
or in the aggregate, have a Material Adverse Effect.

4.7.
No Governmental Authority or Consents. No consent, approval, authorization, order, license, registration or qualification
of or with any court or arbitrator, governmental or regulatory authority is required for the execution, delivery and performance
by the Company of this Agreement, or the issuance and sale of the Note, except such filings as may be required to be made with
the SEC or under any state securities laws, foreign securities laws, blue sky laws, or the rules and regulations of Nasdaq, which
filings shall be made in a timely manner in accordance with all applicable Laws.

4.8.
Litigation. There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending
to which the Company or any of its subsidiaries is a party or to which any property of the Company or any of its subsidiaries is
subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and no such investigations,
actions, suits or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory
authority or threatened by others.

4.9.
Licenses and Other Rights; Compliance with Laws. The Company and its subsidiaries possess or are in the process of
obtaining all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with,
the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or
lease of their respective properties or the conduct of their respective businesses as described in the SEC Documents, except where
the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and neither
the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate,
permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed
in the ordinary course. For the avoidance of doubt and notwithstanding the foregoing, neither the Company nor any subsidiary has
applied for or holds any product licenses or marketing authorizations for any pharmaceutical products.

    	6

     

    

4.10.
SEC Documents; Financial Statements; Nasdaq Stock Market.

(a)
Since January 1, 2020, the Company has timely filed all required reports, schedules, forms, statements and other documents
(including exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, with
the SEC (the “SEC Documents”). As of their respective filing dates, each of the Company SEC Documents complied
in all material respects with the requirements of the 1933 Act and the 1934 Act, and the rules and regulations of the SEC promulgated
thereunder applicable to such Company SEC Documents, and no Company SEC Documents when filed, declared effective or mailed, as
applicable, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

(b)
Since January 1, 2020, the Company has filed all notices and documents required to be filed by it under the Nasdaq listing
rules. Each such notice or document was filed within the applicable timeframe prescribed by the Nasdaq listing rules. As of their
respective dates, each such notice or document complied in all material respects with the applicable requirements of the Nasdaq
listing rules.

(c)
As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC
or its staff.

(d)
The financial statements of the Company for the eleven month period from February 1, 2019 to December 31, 2019 (included
in the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2020) present fairly the financial position
of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes
in their cash flows for the periods specified; such financial statements have been prepared in conformity with GAAP, applied on
a consistent basis throughout the periods covered thereby, except as otherwise disclosed therein and, in the case of unaudited,
interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes, and any supporting
schedules included in the SEC Documents present fairly the information required to be stated therein.

(e)
As of the date hereof, the Common Stock of the Company is admitted to trading on Nasdaq. The Company has taken no action
designed to, or which is likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or delisting
the Common Stock from Nasdaq. The Company has not received any notification that the SEC or Nasdaq, as applicable, is contemplating
terminating such registration or listing.

(f)
The Company and its subsidiaries have established systems of “internal control over financial reporting” (as
defined in Rule 13a-15(f) of the 1934 Act) that have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP,
including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are
executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets
is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

    	7

     

    

(g)
There is and has been no material failure on the part of the Company or any of the Company’s directors or officers,
in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations
promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans and Sections
302 and 906 related to certifications.

4.11.
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three
months ended September 30, 2020 and the three months and six months ended June 30, 2020 have been prepared with all due care and
attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent
with those adopted in the preparation of the audited financial statements of the Company and its consolidated subsidiaries for
the eleven month period ended December 31, 2019 and the corresponding interim results of the Company and its consolidated subsidiaries
for the immediately preceding financial year as published in the Company’s Quarterly Report on Form 10-Q filed with the SEC
on November 16, 2020 and, with respect to the periods ended June 30, 2020, the Company’s Current Report on Form 8-K filed
with the SEC on September 29, 2020, except as otherwise disclosed therein.

4.12.
Absence of Certain Changes. Since the interim results of the Company and its consolidated subsidiaries for the three
months ended September 30, 2020 were prepared, and excluding the organizational changes made in connection with the Domestication:
the businesses of the Company and its consolidated subsidiaries have been carried on in the ordinary and usual course; there has
been no significant adverse change in the financial or trading position of the Company taken as a whole or, to the best of the
Company’s knowledge, information and belief, prospects of the Company; the Company has not acquired or disposed of or agreed
to acquire or dispose of any of its assets or businesses other than in the ordinary course of trading; the Company has not entered
into any contract or commitment of an unusual, long-term and/or onerous nature or assumed any material liabilities (including contingent
liabilities) (other than as contemplated by this Agreement); the Company has not paid or made any payment or transfer to shareholders
of any dividend, bonus, loan or distribution other than to the directors of the Company in their capacity as such directors in
a manner consistent with the compensation of such directors as disclosed in the SEC Documents; and the Company has complied in
all material respects with all the listing requirements of Nasdaq applicable to the Company (including the disclosure and notification
requirements) and any requests for disclosure made by Nasdaq.

4.13.
Tax. All returns of each member of the Group for taxation purposes have been made for all periods up to and including
December 31, 2019, and all such returns are correct, and are not the subject of any dispute with or claim by HM Revenue & Customs
or other relevant taxation authority (other than routine audits) which would be material to the Company are not likely to result
in any such dispute or claim.

4.14.
Environmental. So far as the Company is aware, none of the Company nor any member of the Group has any material obligation
or liability with respect to pollution, hazardous substances or environmental matters and there are no circumstances which the
Company considers are likely to give rise to the same.

4.15.
Insurance. The Company and each member of the Group maintain such insurance coverage against fire and other risks
upon all their assets and such public and employers’ liability as the directors of each such company consider appropriate,
taking into account the nature and scale of their activities, the provisions of agreements binding upon it, such insurance is now
in force. The Company is not aware of any fact or matter which would lead to any such insurance being vitiated or repudiated, there
is no material claim pending or outstanding and all premiums in respect of such insurances are duly paid.

    	8

     

    

4.16.
Intellectual Property.

(a)
Each member of the Group has (i) acted reasonably in seeking professional advice with regard to filing patent applications
in respect of material new inventions; (ii) adopted commercially reasonable and prudent practices with regard to the protection,
prosecution and maintenance of its portfolio of patents, patent applications and trademarks and other material intellectual property
and the payment of renewal fees in respect thereof; (ii) adopted commercially reasonable and prudent practices to capture intellectual
property rights in respect of material new inventions; and (iv) used commercially reasonable practices to protect the confidentiality
of all material non-patented know how. None of the intellectual property relating to the business of any member of the Group is
the subject of any claim, opposition, assertion, infringement, attack, right, action or other restriction or arrangement of whatsoever
nature which does or may impinge upon the validity, enforceability or ownership of the same or the utilization thereof by any member
of the Group to an extent which is material in the context of the Group. So far as the Company is aware, and not having obtained
freedom to operate opinions in respect of all of its intellectual property rights, none of the activities of any member of the
Group infringes in any material respect any right of any other person relating to intellectual property or gives rise to a material
liability for any royalty or similar payment.

(b)
The intellectual property used or enjoyed by each member of the Group in connection with its business at the date of this
Agreement, and which is material to such business, is either legally and beneficially owned by that member of the Group, or licensed
to, or used under the authority of the owner by, that member of the Group and are not subject to any mortgage, charge, lien or
other security interest in favor of any third party save as registered with the United States Patent and Trademark Office or the
Registrar of Companies in the United Kingdom.

4.17.
Offering. Subject to the accuracy of the Investor’s representations set forth in Section 5, the offer, sale
and issuance of the Note to be issued in conformity with the terms of this Agreement, constitute transactions which are exempt
from the registration requirements of the 1933 Act and from all applicable state registration or qualification requirements.

4.18.
No Integration. The Company has not, directly or through any agent, sold, offered for sale, solicited offers to buy
or otherwise negotiated in respect of, any security (as defined in the 1933 Act), that is or will be integrated with the sale of
the Note thereunder in a manner that would require registration of such securities under the 1933 Act.

4.19.
Brokers’ or Finders’ Fees. Neither the Company nor any of its subsidiaries is a party to any contract,
agreement or understanding with any person that would give rise to a valid claim against the Company or any of its subsidiaries
for a brokerage commission, finder’s fee or like payment in connection with the transactions contemplated by this Agreement.

    	9

     

    

4.20.
No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any
of the securities to be issued pursuant to this Agreement by any form of general solicitation or general advertising. The Company
has offered the Note for sale only to the Investor.

4.21.
Foreign Corrupt Practices. None of the Company, any of its subsidiaries, nor to the knowledge of the Company, any
agent or other person acting on behalf of the Company or any of its subsidiaries, has: (i) directly or indirectly, used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political
parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any of its subsidiaries
(or made by any person acting on its or their behalf of which the Company is aware) which is in violation of law or (iv) violated
in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable non-U.S. anti-bribery
Law.

4.22.
Regulation M Compliance. The Company has not taken, directly or indirectly, any action designed to or that would
reasonably be expected to cause or result in stabilization or manipulation of any of its securities to facilitate the sale or resale
of the Note.

4.23.
Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately
following the Closing will not be required to register as, an “investment company” within the meaning of the Investment
Company Act of 1940, as amended.

4.24.
Disclosures. The SEC Documents, when considered together, do not contain any untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under
which they were made, not misleading, other than with respect to the transactions contemplated by this Agreement and except as
will be disclosed pursuant to Section 10.7.

5.
Representations and Warranties of the Investor. The Investor hereby represents and warrants to the Company that:

5.1.
Authority. The Investor is an individual with power and authority to enter into and consummate the transactions contemplated
by this Agreement and to carry out its obligations thereunder, and to invest in the Note pursuant to this Agreement.

5.2.
Authorization. This Agreement has been duly executed and delivered by the Investor, and this Agreement constitutes
a valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with its terms, except as
enforceability may be limited by the Enforceability Exceptions.

5.3.
No Conflicts. The execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated by this Agreement and the other Transaction Documents will not (i) conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge
or encumbrance upon any property or assets of the Investor pursuant to, any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Investor is a party or by which the Investor is bound or to which any of the property
or assets of the Investor is subject, or (ii) result in the violation of any law or statute or any judgment, order, rule or regulation
of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Investor except, in the case of
clauses (i) and (ii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate,
have a material adverse effect on the Investor’s ability to perform its obligations or consummate the transactions contemplated
by this Agreement.

    	10

     

    

5.4.
Purchase Entirely for Own Account. The Note to be received by the Investor hereunder will be acquired for the Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the
1933 Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same
in violation of the 1933 Act, without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose
of all or any part of the Note in compliance with the terms of the Note and any applicable federal and state securities laws.
The Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would
require it to be so registered.

5.5.
Investment Experience. The Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Note and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment contemplated hereby.

5.6.
Disclosure of Information. The Investor has had an opportunity to receive, review and understand all information
related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its
business and the terms and conditions of the offering of the Note, and has conducted and completed its own independent due diligence.
The Investor acknowledges that copies of the SEC Documents are available on the SEC’s EDGAR system. Based on such information
as the Investor has deemed appropriate and the representations and warranties of the Company contained in Section 4 of this Agreement,
and without reliance upon any other party, it has independently made its own analysis and decision to enter into this Agreement.
The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision
with respect to its acquisition of the Note.

5.7.
Restricted Securities. The Investor understands that the Note will be characterized as “restricted securities”
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933
Act only in certain limited circumstances. The Investor acknowledges that the Company has no obligation to register or qualify
the Note for resale. The Investor further acknowledges that if an exemption from registration or qualification is available, it
may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the
Note, and on requirements relating to the Company which are outside of the Investor’s control, and which the Company is under
no obligation and may not be able to satisfy.

5.8.
Legends. It is understood that, the Note bears a restrictive legend in accordance with the requirements of the Securities
Act of 1933 limiting the Investors right to dispose of the Note.

    	11

     

    

5.9.
Accredited Investor. The Investor is an “accredited investor” within the meaning of Rule 501 under the
1933 Act and has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit
C (the “Investor Questionnaire”), which such Investor represents and warrants is true, correct and complete.
The Investor is a sophisticated investor with sufficient knowledge and experience in investing in private equity transactions to
properly evaluate the risks and merits of its purchase of the Note. Such Investor has determined based on its own independent review
and such professional advice as it deems appropriate that its purchase of the Note and participation in the transactions contemplated
by this Agreement (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully consistent
with all investment policies, guidelines and other restrictions applicable to such Investor, (iii) have been duly authorized and
approved by all necessary action, (iv) do not and will not violate or constitute a default under any law, rule, regulation, agreement
or other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding
the substantial risks inherent in investing in or holding the Note.

5.10.
No General Solicitation. The Investor did not learn of the investment in the Note as a result of any general solicitation
or general advertising.

5.11.
Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid
right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to
any agreement, arrangement or understanding entered into by or on behalf of the Investor.

5.12.
Short Sales and Confidentiality Prior to the Date Hereof.  Other than consummating the transactions contemplated
hereunder, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly
or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company or directly or indirectly
engaged in any action designed to, or which might be reasonably expected to, cause or result in any manipulation of the price of
the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company
or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof.  The Investor
has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and
terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a
representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of,
available securities to borrow in order to effect Short Sales or similar transactions in the future.

5.13.
No Government Recommendation or Approval. The Investor understands that no United States federal or state agency,
or similar agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company
or the purchase of the Note.

5.14.
No Rule 506 Disqualifying Activities. The Investor has not taken any of the actions set forth in, and is not subject
to, the disqualification provisions of Rule 506(d)(1) of the 1933 Act.

    	12

     

    

6.
Covenants and Agreements of the Company and the Investor.

6.1.
No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment
that would conflict or interfere in any material respect with the Company’s obligations to the Investor under this Agreement.

6.2.
Removal of Legends.

(a)
In connection with any sale, assignment, transfer or other disposition of the Note by the Investor pursuant to Rule 144
or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable securities and upon compliance
by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall use commercially reasonable
efforts to remove any restrictive legends that appear on the Note and to issue a new, unlegended Note without restrictive legends,
provided that the Company has received from the Investor customary representations and other documentation reasonably acceptable
to the Company in connection therewith and, if necessary, otherwise sufficient to support any required legal opinion with respect
thereto.

(b)
Subject to receipt from the Investor by the Company of customary representations and other documentation reasonably acceptable
to the Company in connection therewith and, if necessary, otherwise sufficient to support any required legal opinion with respect
thereto, upon the earliest of such time as the Note (i) has been sold or transferred pursuant to an effective registration statement,
(ii) has been sold pursuant to Rule 144, or (iii) is eligible for resale under Rule 144(b)(1) or any successor provision
(such earliest date, the “Effective Date”), the Company shall issue a new, unlegended Note. The Company agrees
that following the Effective Date or at such time as such legend is no longer required under this Section 6.2, it will, following
the delivery by the Investor to the Company of the Note issued with a restrictive legend, use commercially reasonable efforts to
deliver or cause to be delivered to such Investor a new, unlegended Note that is free from all restrictive and other legends. The
Company may not make any notation on its records that enlarge the restrictions on transfer set forth in this Section 6.2.

(c)
Subject to the restrictions on dispositions pursuant to Section 7.1 of this Agreement, the Investor agrees with the Company
that the Investor will sell the Note only in compliance with an exemption from the registration requirements of the 1933 Act.

6.3.
Subsequent Equity Sales. The Company shall not, and shall use its commercially reasonable efforts to ensure that
no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale of the Note in a manner that would
require the registration under the 1933 Act of the sale of the Note to the Investor, or that will be integrated with the offer
or sale of the Note for purposes of the rules and regulations of any trading market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

6.4.
Short Sales and Confidentiality After the Date Hereof. The Investor covenants that neither it nor any Affiliates
acting on its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof
until such time as the transactions contemplated by this Agreement are first publicly announced. The Investor covenants that until
such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, the Investor will maintain
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this
transaction). The Investor understands and acknowledges that the SEC currently takes the position that coverage of Short Sales
of securities “against the box” prior to effectiveness of a resale registration statement with securities included
in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in Item 239.10 of the Securities
Act Rules Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance.

    	13

     

    

6.5.
Pro Rata Right. For such period as the Note remains outstanding, the Investor shall have the right to participate
pro rata in a subsequent Company equity financing transaction for up to a portion of such transaction that represents the Investor’s
percentage ownership of the Company’s issued and outstanding equity as of immediately prior to the execution of definitive
documents with third parties for such financing transaction. Any such participation shall be terms and conditions at least equivalent
with such terms as are agreed with any other third party participant in such financing transaction, and the Investor shall be permitted
to apply the principal of the Note to the purchase price of any such investment.

7.
Acknowledgements.

7.1.
Insider Trading. In addition to the restrictions in this Agreement on the Disposition of Common Stock and Common
Stock Equivalents of the Company, the Investor hereby acknowledges that it is aware that United States securities Laws prohibit
any person who has material, non-public information about a company obtained directly or indirectly from that company from purchasing
or selling securities of such company or from communicating such information to any other person, including under circumstances
in which it is reasonably foreseeable that such person is likely to purchase or sell such securities.

8.
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the
Closing of the transactions contemplated by this Agreement for the applicable statute of limitations.

9.
Miscellaneous.

9.1.
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of
the Company or the Investor, as applicable. The provisions of this Agreement shall inure to the benefit of and be binding upon
the respective permitted successors and assigns of the parties.

9.2.
Counterparts; E-mail. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via electronic
mail, which shall be deemed an original.

9.3.
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.

9.4.
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing
and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be
deemed given upon such delivery, (ii) if given by electronic mail, then such notice shall be deemed given upon receipt of confirmation
of complete transmittal, and (iii) if given by an internationally recognized overnight air courier, then such notice shall
be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at
the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other
party:

    	14

     

    

If to the Company:

Summit Therapeutics Inc.

One Broadway, 14th Floor

Cambridge, MA 02142

Attention: Chief Financial Officer

Email: Mike.Donaldson@summitplc.com

With a copy to:

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, New York 10019

Attention: Adam W. Finerman

Email: AFinerman@olshanlaw.com

If to the Investor:

to the address set forth on Exhibit
A hereto.

9.5.
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether
the transactions contemplated hereby are consummated; it being understood that each of the Company and the Investor has relied
on the advice of its own respective counsel and/or other professional advisers.

9.6.
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Investor.

9.7.
Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated
hereby shall be issued by the Investor without the prior consent of the Company (which consent shall not be unreasonably withheld),
except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange
or securities market, in which case the Investor shall allow the Company, to the extent reasonably practicable in the circumstances,
reasonable time to comment on such release or announcement in advance of such issuance. The Company shall not include the name
of the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with
the SEC) without the prior written consent of the Investor, except as otherwise required by law or the applicable rules or regulations
of any securities exchange or securities market, in which case the Company shall allow the Investor, to the extent reasonably practicable
in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Promptly following
the date this Agreement is executed, the Company shall issue a press release disclosing all material terms of transactions contemplated
by this Agreement (the “Press Release”) and make an announcement thereof (including the name of the Investor)
to a Regulatory Investment Service. No later than 5:30 p.m. (New York City time) on the fourth Business Day following the date
this Agreement is executed, the Company will file a Report on Form 8-K (the “8-K Filing”) attaching the press
release described in the foregoing sentence as well as a copy of this Agreement. In addition, the Company will make such other
filings and notices in the manner and time required by the SEC or Nasdaq. The parties acknowledge that from and after the issuance
of the Press Release, the Investor shall not be in possession of any material, nonpublic information received from the Company
or any of its respective officers, directors, employees or agents, with respect to the transactions contemplated hereby that is
not disclosed in the Press Release.

    	15

     

    

9.8.
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provision hereof prohibited or unenforceable in any respect.

9.9.
Entire Agreement. This Agreement, including the signature pages and Exhibits hereto, constitutes the entire agreement
among the parties hereof with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings,
both oral and written, between the parties with respect to the subject matter hereof and thereof.

9.10.
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all
such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

9.11.
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York
County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding
or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection
with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified
for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such
court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any
objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim
that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES
HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL
HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

[remainder of page intentionally left
blank]

    	16

     

    

 

IN WITNESS WHEREOF, the parties have
executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	COMPANY:	
        Summit Therapeutics INC.

         

	 	By:	/s/ Michael Donaldson
	 	 	Name: Michael Donaldson
	 	 	
        Title: Chief Financial Officer

         

 

     

     

    

	INVESTOR:	 
	 	
         

        By:
	

/s/ Robert W. Duggan
	 	 	
        Name: Robert W. Duggan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]